All In Biotech

Drug Trial Radar · NCT05135091

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Jun 16, 2022

Primary completion

Feb 2029

Study completion Sep 2043

Sponsor

Lead sponsor
Neurona TherapeuticsIndustry
Sponsor type
Industry
Collaborators
California Institute for Regenerative Medicine (CIRM)
First posted
Nov 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).

Conditions

  • Mesial Temporal Lobe Epilepsy

Interventions

  • NRTX-1001Biological

    Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.

  • NRTX-1001Biological

    Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.

  • Sham ComparatorProcedure

    Sham Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of serious or severe AEs (Phase 1/2)Time frame: 1 year
  2. Change in disabling seizure frequency (Phase 3)Time frame: 4-6 months after surgery

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Arizona Epilepsy Center

    Phoenix, Arizona · Recruiting

  • Banner-University of Arizona Medical Center Tucson Comprehensive Epilepsy Program

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • University of Southern California Keck Hospital

    Los Angeles, California · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • UC Irvine Medical Center

    Orange, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California Davis

    Sacramento, California · Recruiting

  • University of California San Diego

    San Diego, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • George Washington University

    Washington D.C., District of Columbia · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Wayne State University/Detroit Medical Center Comprehensive Epilepsy Program

    Detroit, Michigan · Recruiting

  • Washington University at St. Louis

    St Louis, Missouri · Recruiting

  • Dartmouth Hitchcock Medical Center/ Department of Neurology

    Lebanon, New Hampshire · Recruiting

  • Kaleida Health

    Buffalo, New York · Recruiting

  • Hofstra Northwell Comprehensive Epilepsy Center

    Great Neck, New York · Recruiting

  • NYU Langone Comprehensive Epilepsy Center

    New York, New York · Recruiting

  • SUNY Upstate Medical University

    Syracuse, New York · Recruiting

  • Atrium Health

    Charlotte, North Carolina · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • Atrium Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • UTHealth Houston

    Houston, Texas · Recruiting

  • University of Utah Health

    Salt Lake City, Utah · Recruiting

  • University of Washington Regional Epilepsy Center

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.